Titan Pharmaceuticals Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for Titan Pharmaceuticals.

Price Target: $0.00 (0.00%)

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for Titan Pharmaceuticals.

Recommendation Trends

Rating	Dec '21	Jan '22	Feb '22	Mar '22	Apr '22
Strong Buy	1	1	1	1	1
Buy	0	0	0	0	0
Hold	0	0	0	0	0
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason McCarthy Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	May 26, 2022
Jason McCarthy Maxim Group	Maxim Group	Hold → Strong Buy Upgrades $220	Hold → Strong Buy	Upgrades	$220	+4,672.23%	Feb 18, 2021
Jason McCarthy Maxim Group	Maxim Group	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Aug 17, 2020
Jason McCarthy Maxim Group	Maxim Group	Hold → Strong Buy Upgrades $600	Hold → Strong Buy	Upgrades	$600	+12,915.18%	Oct 23, 2019
Scott Henry Roth Capital	Roth Capital	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Nov 10, 2017

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

from -5.23

EPS Next Year

n/a

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Revenue	4.84M	1.53M	557.00K	184.00K	-
Revenue Growth	85.72%	-68.46%	-63.50%	-66.97%	-
EPS	-96.70	-18.04	-15.19	-7.41	-5.23
EPS Growth	-	-	-	-	-
Forward PE	-	-	-	-	-
No. Analysts	-	-	-	-	-

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue
High
Avg
Low

Revenue Growth

Revenue Growth
High
Avg
Low

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.